Differential Response of Breast Cancer Patients on E2100 Treated With Bevacizumab as a Function of Genetic Polymorphisms of VEGF and KDR

Brief Summary

Detailed Description

OBJECTIVES: Primary * Assess the effect of known variant polymorphisms (with functionally important associations) of the vascular endothelial growth factor (VEGF) gene on outcome (time to progression) in patients with breast cancer treated with bevacizumab on clinical trial ECOG-2100. Secondary * Assess the effect of known variant polymorphisms (with functionally important associations) of the VEGF receptor-2 (KDR) gene on outcome (time to progression) in these patients. * Assess the effect of known variant polymorphisms of these genes on efficacy (objective response rate and survival) in these patients. * Assess the effect of known variant polymorphisms of these genes on toxicity outcome in these patients. * Assess the effect of VEGF polymorphisms on VEGF expression by immunohistochemical staining (a known prognostic marker). * Assess the effect of KDR polymorphisms on KDR expression by immunohistochemical staining. OUTLINE: This is a multicenter study. Tissue and genomic DNA samples from paraffin-embedded primary tumor are examined using standard polymerase chain reaction (PCR) restriction fragment-length polymorphisms, immunohistochemistry, allele-specific PCR, and/or Taqman-based assays. Vascular endothelial growth factor (VEGF) and VEGF receptor-2 (KDR) expression and polymorphisms are assessed. PROJECTED ACCRUAL: A total of 500 specimens will be accrued for this study.

Primary Outcomes

Secondary Outcomes

• Time to progression in patients with a known polymorphism vs those with wild-type VEGF receptor-2 (KDR) gene
• Difference in response rate, survival, and toxicity in patients with a known polymorphism vs wild-type VEGF and KDR